PT-141
A central-nervous-system melanocortin agonist studied specifically for its role in female sexual response research. PT-141 is one of the most-targeted peptides in women’s libido science.
A peptide developed for women’s biology.
PT-141 (bremelanotide) is a synthetic peptide derived from research into melanocortin receptor pathways. Unlike libido interventions that work through vascular mechanisms, PT-141 acts on the central nervous system — the brain itself — where the earliest signals of sexual interest originate.
For women, this central mechanism is the entire reason PT-141 became significant. The vast majority of libido research has historically focused on male physiology and vascular response. PT-141 emerged from research that recognized female sexual function isn’t primarily a vascular problem — it’s a neurological one.
Published research has documented PT-141’s effects on subjective sexual desire, arousal, and the brain’s response to sexual cues. Bremelanotide has also been the subject of FDA-approved clinical research for hypoactive sexual desire disorder in premenopausal women, making it one of the more well-characterized peptides in women’s sexual health literature.
When research finally caught up to women.
Centrally Acting Mechanism
Studied in Premenopausal Women
Beyond Vascular Response
